Zioga E A M, Arias-de la Torre J, Patera E, Borjabad B, Macorigh L, Ferrer L
Departamento de Medicina Interna, Hospital Dos de Mayo, Barcelona, España.
Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Barcelona, España; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, España; Instituto de Biomedicina (IBIOMED), Universidad de León, León, España.
Semergen. 2020 Apr;46(3):202-207. doi: 10.1016/j.semerg.2019.06.006. Epub 2019 Aug 5.
HIV infection remains an important public health problem worldwide. The traditional preventive measures, such as sexual education, screening, and early antiretroviral treatment initiation, despite having shown their effectiveness, are not enough to control new infections. In this context, Pre-Exposure Prophylaxis (PrEP) has been investigated as a preventive measure. Currently, it has been extensively documented that the administration of antiretroviral treatment in an HIV exposed, but not infected population, could reduce the risk of transmission without significant drawbacks. Despite its high efficacy for HIV prevention, the use of PrEP remains a controversial measure, particularly its cost-effectiveness. For this reason, the access to PrEP is not available for all the HIV risk groups. Therefore, and based on the evidence found, the current approach must be the repercussions of not to implement PrEP, more than its cost or its effectiveness.
艾滋病毒感染在全球范围内仍然是一个重要的公共卫生问题。传统的预防措施，如性教育、筛查和早期启动抗逆转录病毒治疗，尽管已显示出其有效性，但仍不足以控制新感染病例。在此背景下，暴露前预防（PrEP）作为一种预防措施受到了研究。目前，已有大量文献证明，在暴露于艾滋病毒但未感染的人群中给予抗逆转录病毒治疗，可以降低传播风险且无明显弊端。尽管PrEP在预防艾滋病毒方面具有高效性，但其使用仍然是一项有争议的措施，尤其是其成本效益。因此，并非所有艾滋病毒风险群体都能获得PrEP。所以，基于已发现的证据，当前应关注的是不实施PrEP的后果，而非其成本或效果。
